Immunitas Therapeutics

Immunitas Therapeutics is a single cell genomics-based drug discovery company that employs a single cell genomics platform to dissect the biology of immune cells in human tumors, thereby advancing discoveries directly from the bench into meaningful clinical improvements.

Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers.

Immunitas Therapeutics was founded in 2019 by (Longwood Fund) Kai Wucherpfennig, Mario Suvà, & Dane Wittrup. The company is based in Boston, Massachusetts.

 

Immunitas' programs are derived from their platform, a cross-functional, highly integrated, single cell genomics approach that enables rapid target identification and validation in parallel with antibody discovery and engineering.

 

Immunitas' IMT-009, a first-in-class NK and T cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. Immunitas is also advancing IMT-073, a dual-target NK and T cell modulator.

 

Immunitas is backed by Longwood Fund, Leaps by Bayer, Agent Capital, Novartis Venture Fund, Evotec, Medical Excellence Capital (MEC), M Ventures, Alexandria Venture Investments, and others. The company completed a $58M Series B round on Aug 18, 2021. This brings Immunitas' total funding to $97M to date.

 

 

  • Year founded: 2019
  • Funding Info: $97M over 2 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Boston
  • State: Massachusetts
  • Country: United States
Related businesses